

Disclosures

Personal Commercial (6)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|---------------------|---------------------------|--------------------------|-------------------------------------|
| <i>Self</i> | | | |
| Abbott Laboratories | Consultant Fees/Honoraria | Modest (< \$5,000) | Valvular Heart Disease |
| EastEnd Medical | Consultant Fees/Honoraria | Modest (< \$5,000) | Invasive CV Angio and Interventions |
| Egnite | Other - advisory board | None (\$0) | Other |
| JenaValve | Consultant Fees/Honoraria | Significant (>= \$5,000) | Valvular Heart Disease |
| Ninger Medical | Stock | None (\$0) | Valvular Heart Disease |
| VDyne | Consultant Fees/Honoraria | Modest (< \$5,000) | Valvular Heart Disease |

Additional Personal Commercial Disclosures for Education Activities (1)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|----------------------|---------------------------|--------------------|--|
| <i>Self</i> | | | |
| Edwards Lifesciences | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies Valvular Heart Disease |

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (5)

| Trial Name | Trial Sponsor | Trial Funding Source |
|---|------------------------|----------------------|
| Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT) | Abbott Laboratories | |
| CORCINCH-HF | Ancora Heart AccuCinch | |
| Early Feasibility Study VENUS-HF | Precardia | |
| Shockwave assisted large bore access | Shockwave Medical | |
| RELIEVE-HF | V-Wave | |

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (2)

| Year | Case Title | Represented | Description | Compensation |
|-------------|------------------|--|-------------|--------------------|
| <i>Self</i> | | | | |
| 2022 | standard of care | Defendant † HuffPowellBailey | | Modest (< \$5,000) |
| 2021 | Cause of death | Defendant † Huff, Powell, Bailey law office | | Modest (< \$5,000) |

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 2/12/2026

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 2/12/2026

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

On-Going Obligation Agreement | Signed on 2/12/2026

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.